ACA
OKUR

Acorn Capital Advisors’s OnKure Therapeutics OKUR Stock Holding History

Acorn Capital Advisors’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.8M Hold
2,839,674
– – 3.34% 8
2025
Q4 		$8.24M Hold
2,839,674
– – 2.79% 11
2025
Q3 		$7.81M Hold
2,839,674
– – 3.96% 8
2025
Q2 		$6.79M Buy
2,839,674
+1,400,000
+97% +$3.67M 4.44% 8
2025
Q1 		$5.12M Hold
1,439,674
– – 3.42% 10
2024
Q4 		$10.2M Buy
+1,439,674
New +$21.8M 5.51% 8

Other funds holding OKUR

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Acorn Capital Advisors's OKUR Position: Q1 2026 in Review

Acorn Capital Advisors held its OnKure Therapeutics (OKUR) position steady in Q1 2026 at 2,839,674 shares worth $11.8M. The position accounts for 3.34% of the portfolio, ranked #8.

Acorn Capital Advisors first reported a position in OKUR in Q4 2024 and has held it in 6 quarters since. 51 funds tracked by Wall St. Rank hold OKUR as of Q1 2026.

  • Acorn Capital Advisors held 2,839,674 shares of OnKure Therapeutics worth $11.8M as of Q1 2026.
  • Acorn Capital Advisors left its OnKure Therapeutics share count unchanged in Q1 2026.
  • OnKure Therapeutics made up 3.34% of Acorn Capital Advisors's portfolio in Q1 2026, its #8 holding.
  • Acorn Capital Advisors first reported a position in OnKure Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 51 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q1 2026.

Based on Acorn Capital Advisors's 13F filing for Q1 2026, filed 15 May 2026.